Revance Therapeutics, Inc. (RVNC)

NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C.

NASHVILLE, Tenn., May 27, 2025 /PRNewswire/ -- Revance is proud to announce that Blue Lizard® Australian Sunscreen, the #1 best-selling mineral SPF brand in the U.S.*, is celebrating National Sunscreen Day on May 27th with a dynamic digital billboard in New York City's Times Square, capping off Skin Cancer Awareness Month and heading into sun season with a bold message: Be Fearless in the Sun. "We're excited to mark National Sunscreen Day in such a powerful way," said Steve Gallopo, Executive Vice President and Chief Commercial Officer, Consumer Skincare. "This billboard is a monumental celebration of our heritage in mineral sun protection and a call to action for everyone to take sun safety seriously." "Our mission is to make sun protection accessible and easy for the whole family," added Nicole Watson, SVP Global Therapeutics Marketing, Consumer Skincare. "This recent rebrand reflects that, with cleaner formulas, enhanced aesthetics, and the same uncompromising SPF 50 protection people have trusted for years." The Times Square billboard showcases Blue Lizard's newly rebranded and reformulated line of mineral sunscreens. The updated formulas feature 100% mineral active ingredients and are free from fragrances, parabens, phthalates, oxybenzone, and octinoxate – offering the same powerful broad-spectrum UVA/UVB protection the brand is known for, now with a cleaner ingredient profile and modern packaging. "UV exposure is cumulative, and daily use of a broad-spectrum mineral sunscreen, like those from Blue Lizard, can significantly reduce the risk of developing skin cancer," said Dr. Aanand Geria, Board Certified Dermatologist. "Blue Lizard is a brand that I feel confident recommending to my patients and using on my own family knowing they will stay protected." As a proud partner of The Skin Cancer Foundation, Blue Lizard is reinforcing its long-standing commitment to sun safety and skin cancer prevention. This Times Square activation amplifies that mission on a national stage – empowering families to enjoy the sun with confidence and the protection they can trust. For more information about Blue Lizard and its full line of products, visit www.bluelizardsunscreen.com. *Revance calculation based on data reported by Circana database in the Mineral Sunscreen category for the 52-week period ending 4/17/2025. Copyright @2025 Circana, LLC. About Blue Lizard®For nearly 30 years, Blue Lizard has been a trusted name in sun protection, offering a comprehensive range of mineral sunscreens designed to safeguard all skin types. Our dermatologist- and pediatrician-recommended 100% mineral formulas are free from fragrances, parabens, and phthalates that can irritate sensitive skin and are free from oxybenzone and octinoxate, aligning with our "We Love the Reef™" initiative to protect delicate marine ecosystems. Featuring Smart Cap® Technology, Blue Lizard product packaging also lets consumers know when harmful UV rays are present and reminds them to reapply. Blue Lizard is owned by Crown Laboratories, Inc., a Revance company. About Revance Revance is a fast-growing global aesthetics and skincare company focused on providing innovative aesthetics and market-leading skincare offerings throughout every stage of life. With a differentiated portfolio of products spanning 60 countries, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and commercialization of new products and treatments. Learn more at Revance.com, RevanceAesthetics.com, CrownLaboratories.com, and CrownAesthetics.com.

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Revance Therapeutics, Inc. (NASDAQ:RVNC) on behalf of long-term stockholders following a class action complaint that was filed against Revance on January 3, 2025 with a Class Period from February 29, 2024 to December 6, 2024. Our investigation concerns whether the board of directors of Revance have breached their fiduciary duties to the company.

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133949&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133907&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Revance Therapeutics, Inc. (NASDAQ:RVNC) between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), of the important March 4, 2025 lead plaintiff deadline. SO WHAT: If you purchased Revance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133865&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133817&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").

NEW YORK , March 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024.

NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133758&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133725&wire=1 or contact Joseph E. Levi, Esq.

SAN JOSE, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between February 29, 2024 and December 6, 2024, both dates inclusive (the “Class Period”), of the important March 4, 2025 lead plaintiff deadline.

NEW YORK, NY / ACCESS Newswire / March 3, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=133702&wire=1 or contact Joseph E. Levi, Esq.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 4, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON REVANCE THERAPEUTICS, INC. (RVNC), CLICK HERE TO PARTI.